Quintiles/Orion Rx Development Venture Will Start With Three Phase II Drugs
Executive Summary
A drug development venture being formed by the contract research organization Quintiles and the Finnish drug manufacturer Orion will start with at least three drugs in Phase II clinical trials
You may also be interested in...
McKesson/Quintiles Info Services Venture Has Access To 40% Of U.S. Rxs
The McKesson/Quintiles information services joint venture will have access to up to 40% of prescriptions, plus 20% of medical claims in the U.S
PPD Doubles Personnel For Internal Discovery Of Therapeutic Targets
PPD has "nearly doubled" the number of full-time equivalents in its discovery unit dedicated to R&D for internal projects, CEO Fred Eshelman, MD, told analysts during an April 17 conference call.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011